Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. - Wikidata - awgldk - TriplyDB

Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease.

Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease.

http://www.wikidata.org/entity/Q37405468

about

Update and new approaches in the treatment of Castleman disease Emerging treatments in Castleman disease - a critical appraisal of siltuximab Laparoscopic treatment of abdominal unicentric castleman's disease: a case report and literature review Clinical Features and Outcomes of Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-associated Inflammation: Prospective Characterization of KSHV Inflammatory Cytokine Syndrome (KICS).Elevated serum interferon γ-induced protein 10 kDa is associated with TAFRO syndrome.Coinfection with human herpesvirus 8 is associated with persistent inflammation and immune activation in virologically suppressed HIV-infected patients.Contribution of viral mimics of cellular genes to KSHV infection and disease.KSHV-associated multicentric Castleman disease: A tangle of different entities requiring multitarget treatment strategies.Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease Clinical Factors Associated with Long-Term Complete Remission versus Poor Response to Chemotherapy in HIV-Infected Children and Adolescents with Kaposi Sarcoma Receiving Bleomycin and Vincristine: A Retrospective Observational Study 18F-fluorodeoxyglucose Positron Emission Tomography in Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease: Correlation With Activity, Severity, Inflammatory and Virologic Parameters.Induction of Kaposi's Sarcoma-Associated Herpesvirus-Encoded Viral Interleukin-6 by X-Box Binding Protein 1.iNKT cell defects in HHV-8-associated MCD.Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease.KSHV-encoded vIL-6 collaborates with deregulated c-Myc to drive plasmablastic neoplasms in mice.Multicentric Castleman disease: Where are we now?Siltuximab for multicentric Castleman disease.HHV8/KSHV-Positive Lymphoproliferative Disorders and the Spectrum of Plasmablastic and Plasma Cell Neoplasms: 2015 SH/EAHP Workshop Report-Part 3.Kaposi sarcoma herpesvirus pathogenesis.Modulation of the Host Environment by Human Cytomegalovirus with Viral Interleukin 10 in Peripheral Blood.Promotion of Endoplasmic Reticulum-Associated Degradation of Procathepsin D by Human Herpesvirus 8-Encoded Viral Interleukin-6.Clinical and laboratory characterization of 114 cases of Castleman disease patients from a single centre: paraneoplastic pemphigus is an unfavourable prognostic factor.The clinical application of plasma Kaposi sarcoma herpesvirus viral load as a tumour biomarker: results from 704 patients.How Viruses Contribute to the Pathogenesis of Hemophagocytic Lymphohistiocytosis.Multicentric Castleman's Disease and Kaposi's Sarcoma in a HIV-Positive Patient on Highly Active Antiretroviral Therapy.Short-term efficacy of the IL6 receptor antibody tocilizumab in patients with HIV-associated multicentric Castleman disease: report of two cases.Disseminated Kaposi's sarcoma in patients with HIV infection correlates to high serum levels of IL-10.Immune reconstitution disorders in patients with HIV infection: from pathogenesis to prevention and treatment.Treatment of Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease.KSHV induces immunoglobulin rearrangements in mature B lymphocytes.Pediatric Kaposi sarcoma in context of the HIV epidemic in sub-Saharan Africa: current perspectives.Experience with Kaposi Sarcoma Herpesvirus Inflammatory Cytokine Syndrome in a Large Urban HIV Clinic in the United States: Case Series and Literature Review.Biologic Agents in the Treatment of Multicentric Castleman Disease

P2860

Q26740703-35F1776A-8CF8-41F9-8B99-4884F48915DF Q26766554-172C34D2-232B-4AEB-8749-56525C403EB4 Q30234833-83628CA2-DAF4-405A-BC37-9532AE5140EC Q33428328-ABE97688-6763-47F2-B14A-C48848914085 Q33439399-A0664EAF-1F2B-4984-89FB-F1B10F6F5913 Q34061952-1BCEF42A-65A8-4C8A-B2E6-C1CF9C767929 Q34303583-498DA2D1-CDBC-46DF-808F-7731E17A4E6A Q34417383-3963F569-37F8-4CEA-A8AC-A15D2168843C Q34636851-AF306DEA-B6B4-4350-B0C2-68C1125CB4E4 Q35991165-E65CB18C-196B-4AB9-AEBD-71C6B0CF0768 Q36078761-2E8096DF-7D13-4C21-8971-62E63520BB2F Q36433852-0BC82A86-B84B-43CD-8474-7745133F1C16 Q37649535-ED559B14-123B-40AC-8C74-7474DDE2B49C Q38658328-DDCA3AD5-1A6C-4729-8280-4BEA27451A04 Q38686974-BDF339A7-55AE-4273-8E45-40F7A850B565 Q38863770-7E4AD005-0086-4D25-987D-C63E42AE2857 Q39146671-003F084F-86C2-4934-9287-284859F6888E Q39232108-4FB886CB-4798-45E0-A7FE-4578A8A8D6C8 Q40046587-59F1B41E-0774-4B29-B963-EF843456769C Q40222984-4B844ABF-3A5C-4411-B87F-4E0DBB94957A Q40896288-AF50B0E5-F51F-45FA-A322-E4EAF4796FC0 Q41138046-B83274A2-AAD2-4F81-8D59-14075A580857 Q41139979-92DC7D77-F6FE-496E-816A-C5413A5D51CF Q41314439-8DEC33B9-EF5F-44CB-8BCE-C454E498AF09 Q41718738-A70CE561-A414-4804-97BE-8993B0181FBC Q41880852-2659FBF1-A7E5-4255-9363-E6A736F7A33D Q42206138-F1E33A70-8A05-40E3-9F80-E3A117ED952F Q42209595-577C5D4D-97C0-4EDA-8478-93AEA2CE61AB Q47382558-A7337B1D-B44C-4A6D-8B5B-3A5E5A773445 Q52586065-9DF92742-D0EE-46DA-8CD2-5C8D4F1345E1 Q53686620-429E3FDD-BADA-4218-9902-357AD9DCA27F Q55395192-AE5A4C98-3505-4ADC-9021-259A20875448 Q59137206-5B32B850-5FEC-4FA4-A7C6-D06BBE9A9103

P2860

Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease.

http://www.wikidata.org/entity/Q37405468

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 30 October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Human and viral interleukin-6 ...... ulticentric Castleman disease.

@en

Human and viral interleukin-6 ...... ulticentric Castleman disease.

@nl

type

label

Human and viral interleukin-6 ...... ulticentric Castleman disease.

@en

Human and viral interleukin-6 ...... ulticentric Castleman disease.

@nl

prefLabel

Human and viral interleukin-6 ...... ulticentric Castleman disease.

@en

Human and viral interleukin-6 ...... ulticentric Castleman disease.

@nl

P1433

Q37405468-C1AF02EA-4291-4A8E-8D9F-0A15C265CA2B

P1476

Q37405468-7BAAC5DD-C01D-4E1F-B8D8-5A045EE2223E

P2093

Q37405468-32D64FC2-1895-4234-8228-EF2E5168CE29

Q37405468-65275117-6C0C-4780-A2C5-AFD0A0EB0114

Q37405468-748747A8-31AB-4A62-B502-C5B0343336D2

Q37405468-76902B65-FD56-4D35-A825-90A642C97EF1

Q37405468-85CE75E3-89A7-4E34-905A-8A4F7CAB9FB9

Q37405468-A44B1D1C-134A-4B01-A309-CAE94521ED8B

Q37405468-B322CE5B-331D-4690-A3E1-8E6B205A153D

Q37405468-B3EB70A3-3A9F-4881-AB64-1B1B865E41BE

Q37405468-D71D9DCB-1D13-4988-880D-69AAB6A44F8F

Q37405468-DF723433-D0F5-4440-8AE3-F16BAA719706

P2860

Q37405468-0ADE85EE-C26D-4052-B589-57BFC27195B3

Q37405468-1210F630-FACD-4232-927A-B56138E2D4F2

Q37405468-192F6AE3-0BCA-48C0-9DAA-4598F64C27F8

Q37405468-28EA25EA-C050-4C2C-A249-A14ECFF09A32

Q37405468-2EA9F610-D531-4942-81ED-14F6353DD1FB

Q37405468-34C60F55-A068-46D1-BF9E-2E0459E84044

Q37405468-398D6E4C-7544-4725-8973-8B7149E38E8D

Q37405468-3ED4C684-DC86-4753-BEA0-FB8F2A5A05F3

Q37405468-4DA9DB0E-831A-480C-B65F-9459B2E78867

Q37405468-4EDEDEEF-CE96-4AF3-AA9A-9F024F6C5A7B

P304

Q37405468-22F2D8ED-29C4-4D0F-AFF2-02305F983E61

P31

Q37405468-04643F22-7971-4548-9DFD-BCC559D7ED81

P356

Q37405468-8F419BC6-4C7B-4833-B81B-55444DEF2C26

P407

Q37405468-7816F967-E354-4E64-8888-CDE01441D720

P433

Q37405468-E1D9C962-9DAA-4D4B-AE4B-18E3A1D2F9EC

P478

Q37405468-4791CAE1-4EBB-45BD-9F7B-7AC5B44BDDBE

P50

Q37405468-CBE73D5E-5DB2-4219-AF3F-7C38FC27A727

P577

Q37405468-4A4B322D-DC1C-4C02-B3C1-3A337E3E99DD

P5875

Q37405468-82E01D29-B9ED-4748-B0E4-76FF649511E1

P698

Q37405468-AB5A6FFC-22F9-4B9E-B54F-3FCF881F8B90

P921

Q37405468-1e8ffb8a-8131-4ca0-9013-26f988259d90

P932

Q37405468-836065CA-F643-4783-ACA1-1FED86CA6F12

P356

BLOOD-2013-08-519959

P1433

P1476

Human and viral interleukin-6 ...... ulticentric Castleman disease.

@en

P2093

Deirdre O'Mahony

http://www.w3.org/2001/XMLSchema#string

Denise Whitby

http://www.w3.org/2001/XMLSchema#string

Giovanna Tosato

http://www.w3.org/2001/XMLSchema#string

Karen Aleman

http://www.w3.org/2001/XMLSchema#string

Kathleen M Wyvill

http://www.w3.org/2001/XMLSchema#string

Richard F Little

http://www.w3.org/2001/XMLSchema#string

Robert Yarchoan

http://www.w3.org/2001/XMLSchema#string

Seth M Steinberg

http://www.w3.org/2001/XMLSchema#string

Stefania Pittaluga

http://www.w3.org/2001/XMLSchema#string

Thomas S Uldrick

http://www.w3.org/2001/XMLSchema#string

P2860

IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin

Primary Characterization of a Herpesvirus Agent Associated with Kaposi’s Sarcoma

Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma

Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas

Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease

A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients.

Pivotal advance: Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded microRNA specifically induce IL-6 and IL-10 secretion by macrophages and monocytes.

Cellular tropism and viral interleukin-6 expression distinguish human herpesvirus 8 involvement in Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease.

Kinetics of Kaposi's sarcoma-associated herpesvirus gene expression.

Transcription program of human herpesvirus 8 (kaposi's sarcoma-associated herpesvirus).

P304

4189-4198

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2013-08-519959

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

122

http://www.w3.org/2001/XMLSchema#string

P50

Mark N Polizzotto

P577

2013-10-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258204762

http://www.w3.org/2001/XMLSchema#string

P698

24174627

http://www.w3.org/2001/XMLSchema#string

P921

P932

3868925

http://www.w3.org/2001/XMLSchema#string